Johnson & Johnson (NYSE:JNJ) Shares Purchased by Gradient Investments LLC

Gradient Investments LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 10.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 201,459 shares of the company’s stock after purchasing an additional 19,046 shares during the quarter. Johnson & Johnson makes up about 0.9% of Gradient Investments LLC’s investment portfolio, making the stock its 28th largest holding. Gradient Investments LLC’s holdings in Johnson & Johnson were worth $33,346,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Atlantic Private Wealth LLC acquired a new position in Johnson & Johnson in the first quarter worth $32,000. GW&K Investment Management LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at $35,000. Dark Forest Capital Management LP lifted its stake in Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after buying an additional 188 shares during the last quarter. Ruedi Wealth Management Inc. bought a new stake in Johnson & Johnson in the fourth quarter valued at $42,000. Finally, Kepos Capital LP bought a new stake in Johnson & Johnson in the fourth quarter valued at $45,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In related news, insider William Hait sold 14,698 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, insider William Hait sold 14,698 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Trading Up 0.6 %

Shares of JNJ opened at $162.41 on Tuesday. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The business’s 50-day moving average price is $166.21 and its 200 day moving average price is $161.83. The stock has a market capitalization of $422.10 billion, a P/E ratio of 32.88, a P/E/G ratio of 3.26 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. During the same quarter in the previous year, the business posted $2.59 EPS. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.03 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were paid a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.93%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on JNJ. HSBC began coverage on Johnson & Johnson in a research note on Wednesday, September 6th. They issued a “hold” rating and a $175.00 target price on the stock. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Barclays cut their price objective on shares of Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating on the stock in a research note on Friday, September 8th. Wells Fargo & Company cut their price objective on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research note on Thursday, August 31st. Finally, TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. Nine analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $170.65.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.